z-logo
Premium
Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers
Author(s) -
Mellström Britt,
Säwe Juliette,
Bertilsson Leif,
Sjöqvist Folke
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.56
Subject(s) - amitriptyline , hydroxylation , demethylation , nortriptyline , chemistry , pharmacology , metabolism , clinical pharmacology , pharmacokinetics , plasma levels , metabolite , endocrinology , medicine , biochemistry , enzyme , gene expression , dna methylation , gene
Eleven healthy nonsmokers with wide variation in the ability to hydroxylate debrisoquin (D) were given single oral doses of amitriptyline and nortriptyline on different occasions. The urinary D/4‐hydroxy‐D ratio correlated significantly (P < 0.01) with all three parameters of amitryptyline disposition measured (total plasma clearance, clearance by demethylation, and clearance by pathways other than demethylation), with r s = − 0.89, − 0.78, and − 0.83, respectively. In contrast, we failed to demonstrate such correlations in a previous sample of smokers. Our data suggest that there may be a common regulation of the hydroxylation of D and the oxidative metabolism of amitriptyline in nonsmokers. It is hypothesized that an additional demethylase/hydroxylase is induced in smokers that is not involved in D hydroxylation. Clinical Pharmacology and Therapeutics (1986) 39, 369–371; doi: 10.1038/clpt.1986.56

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom